-
Electronic (PDF)
-
Site License
-
Enterprisewide
Diabetic Macular Edema - Pipeline Review, H2 2011
Global Markets Direct, August 2011, Pages: 126
Diabetic Macular Edema - Pipeline Review, H2 2011
Summary
Global Markets Direct’s, 'Diabetic Macular Edema - Pipeline Review, H2 2011', provides an overview of the Diabetic Macular Edema therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Macular Edema, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Macular Edema. 'Diabetic Macular Edema - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Diabetic Macular Edema.
- A review of the Diabetic Macular Edema products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Diabetic Macular Edema pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Diabetic Macular Edema.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Diabetic Macular Edema pipeline depth and focus of Diabetic Macular Edema therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Diabetic Macular Edema Overview
Therapeutics Development
An Overview of Pipeline Products for Diabetic Macular Edema
Diabetic Macular Edema Therapeutics under Development by Companies
Diabetic Macular Edema Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Diabetic Macular Edema Therapeutics - Products under Development by Companies
Diabetic Macular Edema Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Diabetic Macular Edema Therapeutics Development
Abbott Laboratories
Allergan, Inc.
Sanofi-Aventis
Eli Lilly and Company
Eyetech Pharmaceuticals, Inc.
Santen Pharmaceutical Co., Ltd.
Lux Biosciences, Inc.
Novagali Pharma SA
Novartis AG
Pfizer Inc.
OPKO Health, Inc.
iCo Therapeutics Inc.
Mesoblast Ltd
NicOx SA
SANWA KAGAKU KENKYUSHO CO.,LTD.
Regeneron Pharmaceuticals, Inc.
ThromboGenics NV
Molecular Partners AG
Promedior, Inc.
SARcode Corporation
Alimera Sciences, Inc.
Charlesson LLC.
Icon Bioscience, Inc.
Ampio Pharmaceuticals, Inc.
Diabetic Macular Edema - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Lucentis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Macugen - Drug Profile
Product Description
Mechanism of Action
R&D Progress
iCo-007 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ozurdex - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Perceiva - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Trilipix - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Triamcinolone Acetonide - Drug Profile
Bevacizumab + Triamcinolone Acetonide - Drug Profile
Intravitreal Triamcinolone Injections - Drug Profile
Triamcinolone Acetonide - Drug Profile
Intravitreal Pentraxin-2 - Drug Profile
Diabetic Macular Edema Therapeutics – Drug Profile Updates
Diabetic Macular Edema Therapeutics - Discontinued Products
Diabetic Macular Edema - Featured News
Aug 17, 2011: Regeneron To Present Data From EYLEA Clinical Studies At ASRS 2011 Annual Meeting
Aug 15, 2011: iCo Therapeutics Announces Key iCo-007 Clinical Development Milestone
Jul 14, 2011: NICE Unable To Recommend Drug To Treat Diabetic Macular Edema
Jun 28, 2011: Genentech Announces Positive Results From Two Pivotal Phase III Trials Of Lucentis
May 13, 2011: iCo Therapeutics Engages Ora For Ophthalmic Clinical And Regulatory Guidance
May 13, 2011: Alimera Sciences Resubmits New Drug Application For ILUVIEN
May 03, 2011: Alimera Presents New Safety And Efficacy Results From Phase III Fame Study Of Iluvien In Patients With Diabetic Macular Edema At 2011 Arvo Annual Meeting
Apr 28, 2011: Molecular Partners Reports Positive Results From First Clinical Studies
Apr 08, 2011: Regeneron And Bayer Start Phase III Clinical Program In Diabetic Macular Edema
Mar 25, 2011: Genentech Announces Second Lucentis Phase III Study Meets Primary Endpoint For Improved Vision In Patients With Diabetic Macular Edema
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products Under Development for Diabetic Macular Edema, H2 2011
Products under Development for Diabetic Macular Edema – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Early Clinical Stage Development, H2 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Abbott Laboratories, 2011
Allergan, Inc., 2011
Sanofi-Aventis, 2011
Eli Lilly and Company, 2011
Eyetech Pharmaceuticals, Inc., 2011
Santen Pharmaceutical Co., Ltd., 2011
Lux Biosciences, Inc., 2011
Novagali Pharma SA, 2011
Novartis AG, 2011
Pfizer Inc., 2011
OPKO Health, Inc., 2011
iCo Therapeutics Inc., 2011
Mesoblast Ltd, 2011
NicOx SA, 2011
SANWA KAGAKU KENKYUSHO CO.,LTD., 2011
Regeneron Pharmaceuticals, Inc., 2011
ThromboGenics NV, 2011
Molecular Partners AG, 2011
Promedior, Inc., 2011
SARcode Corporation, 2011
Alimera Sciences, Inc., 2011
Charlesson LLC., 2011
Icon Bioscience, Inc., 2011
Ampio Pharmaceuticals, Inc., 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Diabetic Macular Edema Therapeutics – Drug Profile Updates
Discontinued Products
List of Figures
Number of Products under Development for Diabetic Macular Edema, H2 2011
Products under Development for Diabetic Macular Edema – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Mid Clinical Stage Products, H2 2011
Early Clinical Stage Products, H2 2011
Discovery and Pre-Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW4
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
